MYRIAD GENETICS INC Form 8-K May 06, 2008

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2008

# MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 0-26642 (Commission File Number) 320 Wakara Way

87-0494517 (IRS Employer Identification No.)

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (801) 584-3600

#### Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Dra commencement communications guessent to Dula 12a 4(a) under the Evolution Act (17 CED 240 12a 4(a))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Page 1 of 4 pages

#### ITEM 2.02 Results of Operations and Financial Condition

On May 6, 2008, Myriad Genetics, Inc. announced its financial results for the three and nine months ended March 31, 2008. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### ITEM 9.01 Financial Statements and Exhibits.

(d)

Exhibit	
Number	Description

99.1 Earnings release dated May 6, 2008 for the three and nine months ended March 31, 2008.

Page 2 of 4 pages

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# MYRIAD GENETICS, INC.

Date: May 6, 2008

By: /s/ Peter D. Meldrum
Peter D. Meldrum

President and Chief Executive Officer

Page 3 of 4 pages

# EXHIBIT INDEX

### Exhibit Number Description

99.1 Earnings release dated May 6, 2008 for the three and nine months ended March 31, 2008.

Page 4 of 4 pages